2021 (11 POSTS)

Hathway J, Miller-Wilson L, Sharma A, Jensen I, Yao W, Raza S, et al. 2021. The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population. J Mark Access Health Policy, 9(1):1948670; doi: 10.1080/20016689.2021.1948670.

View Abstract

Yin W, Nie Z, Dingley K, Trzoss M, Krilov G, Marshall N et al. 2021. Characterization of potent paracaspase MALT1 inhibitors for hematological malignancies. Blood 138 (Supplement 1):1187; doi: 10.1182/blood-2021-153159.

View Abstract

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969. PMID: 34089813.

View Abstract

Alexander DD, Pastula ST, Riordan AS. 2021. Epidemiology of lung cancer among acrylonitrile-exposed study populations: A meta-analysis. Regul Toxicol Pharmacol 122(June):104896; doi: 10.1016/j.yrtph.2021.104896. PMID: 33617939.

View Abstract

Hathway J, Miller-Wilson L, Yao W, Jensen I, Weinstein M, Parks P. 2021. The health economic impact of varying levels of adherence to colorectal screening on providers and payers. J Med Econ 24(1):69–78; doi: 10.1080/13696998.2020.1858607.

View Abstract

Bylsma L, Nielson C, Fryzek J, Saad H, Crawford J. Edit chemotherapy relative dose intensity, overall survival, and hematologic toxicity in solid-tumor cancer patients: A literature review and meta-analysis. Poster presentation [preview] at 37th ICPE (International Conference on Pharmacoepidemiology & Therapeutic Rick Management), Virtual, August 2021.

View Abstract

Ierardi AM, Lotter JT, Jacobs N, Finley BL, Pierce JS. Derivation of a proposed asbestiform tremolite NOAEL for lung cancer. Virtual poster Presentation at Society of Toxicology 60th Annual Meeting, Virtual, 2021.

Chappell GA, Wikoff DS, Thompson CM. 2021. Assessment of mechanistic data for hexavalent chromium-induced rodent intestinal cancer using the key characteristics of carcinogens. Toxicol Sci 180(1):38–50; doi: 10.1093/toxsci/kfaa187. PMID: 33404626.

View Abstract

2020 (22 POSTS)

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198; doi: 10.14740/gr1167.

View Abstract

Cohen S, Reichert H, Kansal AR, Chung KC. Improved efficiency of cancer screening with multi-cancer early detection test. International Society for Pharmacoeconomics and Outcomes Research, Inc. (ISPOR) Virtual Conference, May 2020.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

View Abstract

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

View Abstract

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

View Abstract

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

View Abstract

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

View Abstract

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.

View Abstract

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

View Abstract

Lafranconi M, Budinsky R, Corey L, Haws L, Klapacz J, Chappell G, Golden R. Exposure to 1,4-dioxane above the metabolic saturation threshold induces a mitogenic key element in the mouse liver cancer mode of action. Abstract #1505. Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

View Abstract

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

View Abstract